Vaccines for Chandipura Virus

Vaccination is considered as an important control measure considering the high mortality and localized distribution of childhood diseases. Creative Biolabs has a professional team and an advanced vaccine technology platform to develop efficient vaccines to meet the needs of customers.

Chandipura Virus

Chandipura virus (CHPV), a member of the Rhabdoviridae family, Vesiculovirus genus, is considered to be a pathogen of a highly lethal similar to encephalitis. After the outbreak in Andhra Pradesh and Maharashtra from 2003 to 2004, it caught the attention of the whole world. The performance of CHPV begins with influenza-like illness and is associated with abdominal pain, vomiting, altered consciousness, and impaired neurological function. Furthermore, it could cause encephalitis, which is a diffuse or focal inflammatory process of the brain parenchyma associated with brain dysfunction. The disease is characterized by a sudden high fever, followed by seizures, sensory changes, diarrhea and vomiting, followed by death in most cases.

Vaccines for Chandipura Virus

The development and evaluation of subunit vaccines have recently been reported, which have produced good immunogenicity in experimental animals. In addition, the development of tissue culture-based inactivated vaccines against viruses is also a candidate for the prevention and treatment of CHPV.

Inactivated Vaccines

A BPL-inactivated CHPV vaccine based on Vero E6 cells was developed and the immunogenicity in the mice was evaluated. The vaccine produces high antibody titers and is effective in protecting mice from CHPV infecting. Due to its ease of management and downstream processing, the vaccine chose the Vero E6 cell line for large-scale virus propagation. B-Propio lactone (BPL) has become an important inactivating agent and is being widely used in vaccine production. It retains the antigenicity and immunogenicity of viral proteins, so purified viruses are inactivated by BPL. Since the immunogenicity of inactivated vaccines is limited, it is necessary to add an adjuvant (such as to enhance the immunogenicity of the viral vaccine).

Subunit Vaccines

The CHPV genome encodes five polypeptides, namely nucleocapsid protein N, phosphoprotein P, matrix protein M, glycoprotein G and large protein L, of which G protein acts as the major antigenic determinant, protruding from the membrane and functioning. Studies of vesicular stomatitis virus (VSV) and rabies virus (both belonging to the Rhabdoviridae) have shown that G protein may be a good candidate vaccine. Therefore, the G protein of CHPV is the first choice for the development of the vaccine. The recombinant glycoprotein expressed by the baculovirus expression system plays an important role in protecting mice from viral intracerebral attacks, so the protein will provide an excellent candidate vaccine for controlling CHPV with high mortality in children from the endemic areas in India.

For many years, Creative Biolabs has focused on vaccine development and production. We offer a full range of services such as antigen screening, protocol design, adjuvant selection, and vaccine efficiency assessment for our global customers. If you have any needs, just feel free to contact us.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.